Antimicrobial interactions (synergy) of teicoplanin with two broad- spectrum drugs (cefotaxime, ofloxacin) tested against Gram-positive isolates from Germany and the United States

Diagnostic Microbiology and Infectious Disease

Volumn 29, Issue 2, 1997, Pages 87-94

  Jones, Ronald N ^a   Marshall, Steven A ^a   Grimm, Heinz ^b  

^a UNIVERSITY OF IOWA   (United States)

^b Infektionsepidemiologie I ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; DEACETYLCEFOTAXIME; GLYCOPEPTIDE; OFLOXACIN; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG POTENTIATION; ENTEROCOCCUS; GERMANY; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CEFOTAXIME; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE; DRUG SYNERGISM; GERMANY; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; TEICOPLANIN; UNITED STATES;

EID: 0030732024     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(97)00124-7     Document Type: Article

References (25)

1. Bajaksouzian S, Visalli MA, Jacobs MR, Appelbaum PC (1996) Antipneumococcal activities of cefpirome and cefotaxime, alone and in combination with vancomycin and teicoplanin, determined by checkerboard and time-kill methods. Antimicrob Agents Chemother 40:1973-1976.
2. Barr JG, Smyth ETM, Hogg GM (1990) In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis 9:804-809.
3. Brogden RN, Peters GH (1994) Teicoplanin: A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 47:823-854.
4. Cabone M, Fera MT, Calapai M, Focà A (1990) In vitro study of synergistic activity between teicoplanin and imipenem, and teicoplanin and ampicillin, against Staphylococcus strains. Med Sci Res 18:479-481.
5. Campoli-Richards DM, Brogden RN, Faulds D (1990) Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 40:449-486.
6. Chen HY, Williams JD (1984) The activity of vancomycin and teicoplanin alone and in combination with gentamicin or ampicillin against Streptococcus faecalis. Eur J Clin Microbiol 3:436-438.
7. Greenwood D (1988) Microbiological properties of teicoplanin. J Antimicrob Chemother 21(suppl A):1-13.
8. Harding I (1997) Successful treatment of vancomycin-resistant enterococcal (VRE) infections with teicoplanin. J Clin Microbiol Infect 3(suppl 2):174.
9. Jones RN, Johnson DM, Barrett MS, Erwin ME (1991) Antimicrobial activity of isepamicin (Sch 21420, 1-N-HAPA gentamicin B) combinations with cefotaxime, ceftazidime, ceftriaxone, ciprofloxacin, imipenem, mezlocillin, and piperadllin tested against gentamicin-resistant and susceptible gram-negative bacilli and enterococci. J Chemother 3:289-294.
10. Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H (1986) Prospective randomised comparison of three antibiotic regimens for empirical therapy of suspected bacteraemic infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 29:52-57.
11. Leclercq R, Bingen E, Su QH, Lambert-Zechovski N, Courvalin P et al (1991) Effects of combinations of β-lactams, daptomycin, gentamicin, and glycopeptides against glycopeptide-resistant enterococci. Antimicrob Agents Chemother 35:92-98.
12. National Committee for Clinical Laboratory Standards (1993) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically (3rd ed). Approved Standard M7-A3. National Committee for Clinical Laboratory Standards. Wayne, PA: NCCLS.
13. National Committee for Clinical Laboratory Standards (1995) Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-S6. National Committee for Clinical Laboratory Standards. Wayne, PA: NCCLS.
14. Neu HC, Labthavikul P (1983) In vitro activity of teichomycin compared with those of other antibiotics. Anti-microb Agents Chemother 24:425-428.
15. Newsom SWB (1996) Susceptibility of coagulase-negative staphylococci to teicoplanin. Clin Microbiol Infect 2:155-158.
16. Shanson DC, Tadayon M (1986) Activity of teicoplanin compared with vancomycin alone, and combined with gentamicin, against penicillin tolerant viridans streptococci and enterococci causing endocarditis. J Hosp Infect 7(suppl A):65-72.
17. Special double issue. Cefotaxime in the 90's: A workshop for appropriate broad-spectrum cephalosporin utilization (1995) Diagn Microbiol Infect Dis 22:1-247.
18. Spitzer PG, Eliopoulos GM, Karchmer AW, Moellering RC Jr (1988) Synergistic activity between vancomycin or teicoplanin and gentamicin or tobramycin against pathogenic diphtheroids. Antimicrob Agents Chemother 32:434-437.
19. Thamlikitkul GV (1991) Synergy study of vancomycin or teicoplanin plus gentamicin against enterococci, Staphylococcus aureus and coagulase-negative staphylococci by time-kill method. J Med Assoc Thailand 74:669-674.
20. Todd PA, Faulds D (1991) Ofloxacin: A reappraisal of its antimicrobial activity, pharmacology, and therapeutic use. Drugs 42:825-876.
21. Tuazon CU, Miller H (1984) Comparative in vitro activities of teichomycin and vancomycin alone and in combination with rifampin and aminoglycosides against staphylococci and enterococci. Antimicrob Agents Chemother 25:411-412.
22. Van der Auwera P, Klastersky J (1987) Bactericidal activity and killing rate of serum in volunteers receiving teicoplanin alone or in combination with oral or intravenous rifampin. Antimicrob Agents Chemother 31:1002-1005.
23. Varaldo PE, Debbia E, Schito GC (1983) In vitro activity of teicomycin and vancomycin alone and in combination with rifampin. Antimicrob Agents Chemother 23:402-406.
24. Watanakunakorn C (1987) In vitro activity of teicoplanin alone and in combination with rifampicin, gentamicin, or tobramycin against coagulase-negative staphylococci. J Antimicrob Chemother 19:439-443.
25. Wood MJ (1996) The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 37: 209-222.